Hematology, Transfusion and Cell Therapy (Nov 2021)

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia

  • Adriana Seber,
  • Claudio Galvão de CastroJunior,
  • Lucila N. Kerbauy,
  • Alexandre V. Hirayama,
  • Carmem Bonfim,
  • Juliana Folloni Fernandes,
  • Mair Souza,
  • Rony Schafell,
  • Samir Nabhan,
  • Sandra Regina Loggetto,
  • Belinda Pinto Simões,
  • Vanderson Rocha,
  • Marcos de Lima,
  • Renato L. Guerino-Cunha,
  • Henrique Bittencourt

Journal volume & issue
Vol. 43
pp. S13 – S21

Abstract

Read online

Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytokine release syndrome (CRS) and neurological toxicities (ICANS). This manuscript aims to provide a consensus of specialists in the fields of Hematology Oncology and Cellular Therapy to make recommendations on the current scenario of the use of CAR-T cells in patients with ALL.

Keywords